These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 20143052)

  • 1. Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure--an impact similar to male gender or smoking in schizophrenic patients.
    Ghotbi R; Mannheimer B; Aklillu E; Suda A; Bertilsson L; Eliasson E; Osby U
    Eur J Clin Pharmacol; 2010 May; 66(5):465-74. PubMed ID: 20143052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association of genetic polymorphisms in CYP1A2, UGT1A4, and ABCB1 with autonomic nervous system dysfunction in schizophrenia patients treated with olanzapine.
    Hattori S; Suda A; Miyauchi M; Shiraishi Y; Saeki T; Fukushima T; Fujibayashi M; Tsujita N; Ishii C; Ishii N; Moritani T; Saigusa Y; Kishida I
    BMC Psychiatry; 2020 Feb; 20(1):72. PubMed ID: 32070304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP).
    Nozawa M; Ohnuma T; Matsubara Y; Sakai Y; Hatano T; Hanzawa R; Shibata N; Arai H
    Ther Drug Monit; 2008 Feb; 30(1):35-40. PubMed ID: 18223460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations.
    Czerwensky F; Leucht S; Steimer W
    Ther Drug Monit; 2015 Apr; 37(2):152-60. PubMed ID: 25090458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients.
    Bergemann N; Frick A; Parzer P; Kopitz J
    Pharmacopsychiatry; 2004 Mar; 37(2):63-8. PubMed ID: 15048613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.
    Laika B; Leucht S; Heres S; Schneider H; Steimer W
    Pharmacogenomics J; 2010 Feb; 10(1):20-9. PubMed ID: 19636338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UGT1A4*3 encodes significantly increased glucuronidation of olanzapine in patients on maintenance treatment and in recombinant systems.
    Haslemo T; Loryan I; Ueda N; Mannheimer B; Bertilsson L; Ingelman-Sundberg M; Molden E; Eliasson E
    Clin Pharmacol Ther; 2012 Aug; 92(2):221-7. PubMed ID: 22713701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants.
    Erickson-Ridout KK; Zhu J; Lazarus P
    Pharmacogenet Genomics; 2011 Sep; 21(9):539-51. PubMed ID: 21750471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine.
    Carrillo JA; Herráiz AG; Ramos SI; Gervasini G; Vizcaíno S; Benítez J
    J Clin Psychopharmacol; 2003 Apr; 23(2):119-27. PubMed ID: 12640212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interindividual variation in olanzapine concentration influenced by UGT1A4 L48V polymorphism in serum and upstream FMO polymorphisms in cerebrospinal fluid.
    Mao M; Skogh E; Scordo MG; Dahl ML
    J Clin Psychopharmacol; 2012 Apr; 32(2):287-9. PubMed ID: 22388157
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacokinetics of olanzapine in Chinese male schizophrenic patients with various smoking behaviors.
    Wu TH; Chiu CC; Shen WW; Lin FW; Wang LH; Chen HY; Lu ML
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1889-93. PubMed ID: 18796323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cigarette smoking and heavy coffee consumption affecting response to olanzapine: The role of genetic polymorphism.
    Djordjevic N; Radmanovic B; Cukic J; Baskic D; Djukic-Dejanovic S; Milovanovic D; Aklillu E
    World J Biol Psychiatry; 2020 Jan; 21(1):29-52. PubMed ID: 30513034
    [No Abstract]   [Full Text] [Related]  

  • 13. High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug.
    Skogh E; Sjödin I; Josefsson M; Dahl ML
    J Clin Psychopharmacol; 2011 Feb; 31(1):4-9. PubMed ID: 21192135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine.
    Haslemo T; Eikeseth PH; Tanum L; Molden E; Refsum H
    Eur J Clin Pharmacol; 2006 Dec; 62(12):1049-53. PubMed ID: 17089108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of UGT1A4 and UGT2B7 polymorphisms on lamotrigine plasma concentration in patients with bipolar disorder.
    Zhao T; Zhang HL; Feng J; Cui L; Sun L; Li HJ; Yu LH
    Pharmacogenet Genomics; 2024 Oct; 34(8):261-267. PubMed ID: 39171428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study.
    Ujike H; Nomura A; Morita Y; Morio A; Okahisa Y; Kotaka T; Kodama M; Ishihara T; Kuroda S
    J Clin Psychiatry; 2008 Sep; 69(9):1416-22. PubMed ID: 19193342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cigarette smoking has a differential effect on the plasma level of clozapine in Taiwanese schizophrenic patients associated with the CYP1A2 gene -163A/C single nucleotide polymorphism.
    Huang HC; Lua AC; Wu LS; Wu BJ; Lee SM; Liu CZ
    Psychiatr Genet; 2016 Aug; 26(4):172-7. PubMed ID: 27203225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone.
    Jovanović N; Božina N; Lovrić M; Medved V; Jakovljević M; Peleš AM
    Eur J Clin Pharmacol; 2010 Nov; 66(11):1109-17. PubMed ID: 20563569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of impact of CYP1A2 genetic polymorphism (C/A polymorphism at position 734 in intron 1 and G/A polymorphism at position -2964 in the 5'-flanking region of CYP1A2) on the plasma concentration of haloperidol in smoking male Japanese with schizophrenia.
    Shimoda K; Someya T; Morita S; Hirokane G; Yokono A; Takahashi S; Okawa M
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Feb; 26(2):261-5. PubMed ID: 11817502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of CYP1A2, CYP2C19, and CYP2D6 genotype- and phenoconversion-predicted enzyme activity on clozapine exposure and symptom severity.
    Lesche D; Mostafa S; Everall I; Pantelis C; Bousman CA
    Pharmacogenomics J; 2020 Apr; 20(2):192-201. PubMed ID: 31616047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.